Skip to main content
. Author manuscript; available in PMC: 2015 Aug 15.
Published in final edited form as: Cancer. 2014 Apr 25;120(16):2482–2489. doi: 10.1002/cncr.28674

Table II. Toxicities Grade 3 or Higher Observed in > 10% of Patients during Induction cycles I and II.

Adverse Event ≥ Grade 3 Induction, Cycle I (N=49) Induction, Cycle II (N=31)
N % N %
Febrile neutropenia 20 41% 9 29%
Infections and infestations 23 47% 13 42%
Hypokalemia 10 20% 10 32%
Anorexia 7 14% 2 6%
Diarrhea 6 12% 3 10%
Nausea 6 12% 2 6%
Hyperglycemia 6 12% 2 6%
Alanine aminotransferase increased 6 12% 6 19%
Aspartate aminotransferase increased 4 8% 3 10%